Contract with Celtic Pharma

Fulcrum Pharma PLC
12 April 2006






For immediate release                                              12 April 2006



                               FULCRUM PHARMA PLC

                  ('Fulcrum' or 'the Group' or 'the Company')



             Significant Service Contract signed with Celtic Pharma



Fulcrum Pharma plc (AIM: FUL), the drug development and strategic outsourcing
services company, is pleased to announce the signing of a significant three-year
agreement with Celtic Pharma Development Services Bermuda Ltd. ('Celtic').
Under the terms of this agreement Fulcrum will provide drug development services
to Celtic in Europe, US and Japan.

Celtic is a leading global private equity firm focused on pharmaceutical and
biotechnology products.  Celtic builds value in differentiated and commercially
attractive pharmaceutical products by driving them through the final stages of
the drug approval process, employing a rigorous 'virtual pharma' model of drug
development.  Fulcrum has a proven record in developing new drugs efficiently
and cost effectively using its global, virtual, drug development services model.
Fulcrum's services offer an excellent strategic fit with Celtic and Fulcrum is
well placed to contribute to Celtic's success.  Initially Fulcrum will be
leveraging its virtual model to support the development of four of Celtic's late
stage clinical programmes, specifically the brain cancer treatment TransMID, the
two anti-addiction vaccines, TA-CD and TA-NIC, plus, outside of the USA, the
treatment for brain oedema, Xerecept.

Jon Court, CEO, of Fulcrum Pharma, commented: 'Our management team is delighted
to become a drug development partner with Celtic.  Our company, being an
originator of the virtual model, shares Celtic's enthusiasm for the
effectiveness and efficiency of virtual development.  This agreement strengthens
Fulcrum and represents a further significant step in the development of
Fulcrum's partnership strategy.'

'Fulcrum has the experience, resources and quality to help us add value to our
important therapeutic products,' said John Mayo, Joint General Managing Partner
of Celtic Pharma.  'We look forward to a long and successful relationship with
the Fulcrum team.'

Dr. Patrick O'Connor, Head of Clinical Development for Celtic Pharma Development
Services, added: 'We see the Fulcrum team as an essential addition to our
in-house resources as we look to leverage our team to deliver high quality
development products to the regulatory authorities in the key markets.  We are
actively working with the Fulcrum team to ensure that the first four candidates
move forward rapidly.'







FOR FURTHER INFORMATION, PLEASE CONTACT:


Fulcrum Pharma PLC                                            Tel: [phone]
Jon Court, Chief Executive

Buchanan Communications                                       Tel: [phone]
Mary-Jane Johnson





Notes for editors



About Fulcrum Pharma plc



Fulcrum Pharma plc is an independent, drug development company that is the first
to offer global virtual drug development and strategic outsourcing services to
the pharmaceutical industry.  The Group has expertise in the design, execution
and delivery of drug development programmes and relies on state of the art
information technology and infrastructure in the supply of its services.



Through Fulcrum's services to its clients, the Directors believe that there is
the capacity to deliver products faster and more efficiently to the global
pharmaceutical market. Fulcrum does this by using its skills in the design of
drug programmes that deliver the necessary information for decision-making and
product registration. In so doing, Fulcrum works closely with its clients to
meet their strategic R&D goals.



Fulcrum Pharma is listed on the Alternative Investment Market of the London
Stock Exchange having successfully floated in March 2000.



About Celtic Pharmaceutical Holdings L.P.

Celtic Pharmaceutical Holdings L.P. (Celtic Pharma) is a global private equity
investment firm focused on the biotechnology and pharmaceutical industries.
Celtic Pharma was founded by Stephen Evans-Freke and John Mayo CBE and is based
in Bermuda, with offices in New York and London.  Celtic Pharma acquires and
invests in late stage pharmaceutical programmes and manages these programmes
through to regulatory approval.  Celtic Pharma's aim is to bridge the gap
between the established pharmaceutical companies' new product pipeline crisis
and the biotech industry's capital drought.  For further information, please
visit Celtic Pharma's website at www.celticpharma.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange